Hims Enters Australia with Pilot Rebrand in $1 Billion Global Push

Hims & Hers Health has launched operations in Australia by rebranding local men’s clinic Pilot, setting its sights on a 1 billion dollar international annual revenue target within three years.

The transition gives the New York-listed group immediate access to a domestic telehealth market projected to reach 2.56 billion dollars by 2034. It also establishes the company’s first operating foothold in the Asia-Pacific region following its takeover of Sydney-based parent Eucalyptus earlier this year.

How the Transition Operates

Existing Pilot patients will transfer directly to the Hims platform, keeping their current treatment plans and practitioner links. Roughly 30 percent of the platform’s patient base lives in regional and rural Australia, where physical clinic access remains thin and appointment wait times run long.

Former Eucalyptus chief executive Tim Doyle leads the international division as senior vice president, running Australian operations alongside country general manager Gus Wood. Dr Matt Vickers serves as chief medical officer for the local entity to oversee clinical governance and domestic regulatory standards.

Pilot proved that Australian men want a different model of healthcare: one that is proactive, personal, and built around their lives.

The Read Across for Digital Health

Consolidating Eucalyptus under the core Hims identity shows how direct-to-consumer health brands are moving away from multi-brand regional stables toward single global flags. Maintaining separate platforms in every territory drives up customer acquisition costs and fragments marketing spend. By putting its primary brand on Australian screens, Hims can funnel global brand marketing and technology infrastructure straight into a market with high average revenue per user.

The risk lies in consumer attachment and regulatory scrutiny. Digital health platforms in Australia face strict advertising rules around prescription treatments and compounding pharmacies, alongside tight supervision from medical boards. Pilot built significant local recognition, and erasing the name risks alienating repeat customers if the migration disrupts prescription delivery or doctor consultations.

The Steps That Led Here

Hims & Hers completed its buyout of Eucalyptus earlier this year, securing established patient networks in Australia and the United Kingdom. Eucalyptus had originally built discrete vertical brands including Pilot for men, Kin for fertility, and Software for dermatology, proving out direct-to-door medicine across Australasia before selling to the San Francisco operator.

Market watchers will track whether Hims rebrands the remaining Eucalyptus product lines across women’s health and dermatology, and whether Australian patient numbers keep the company on course for its 1 billion dollar international revenue goal by 2029.